Product Description
ANJ-900 is being developed by Anji Pharma for the treatment of type 2 diabetes in patients with chronic kidney disease. (Sourced from: https://anjipharma.com/pipeline/anj900/)
Mechanisms of Action: Gluconeogenesis Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Anji Pharma
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2020-000763-23 |
2020-000763-23 | P3 |
Active, not recruiting |
Type 2 Diabetes |
2024-06-20 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/16/2023 |
News Article |
Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810 |
|
12/01/2022 |
News Article |
Latest Updates of 12 Viva's Portfolio Companies |
|
10/19/2022 |
News Article |
Anji Pharma and Population Health Partners Enter into Strategic Collaboration to Jointly Address High Prevalence Human Disease |
|
06/02/2022 |
News Article |
Anji Pharma Provides Update on ANJ900 Pivotal Program |